Biopolymer albumin for diagnosis and in drug delivery

Drug Development Research

Volumn 58, Issue 3, 2003, Pages 219-247

  Patil, Gayathri V ^a,b  

^a K L E S S COLLEGE OF PHARMACY   (India)

^b JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

Author keywords

Albumin; Diagnostic agent; Drug delivery; Evaluation; In vitro release; In vivo release; Microbubbles; Microspheres; Nanosphere; Preparation

Indexed keywords

1 VINYL 2 PYRROLIDINONE; ACETOACETIC ACID DERIVATIVE; ADRENALIN; ALBUMIN; ALBUNEX; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; BIOPOLYMER; BOVINE SERUM ALBUMIN; DOXORUBICIN; ECHO CONTRAST MEDIUM; FS 069; GELATIN; GLUTARALDEHYDE; HUMAN SERUM ALBUMIN; MICROSPHERE; MINERAL OIL; NANOPARTICLE; NITROFURANTOIN; OVALBUMIN; POLY(METHYL METHACRYLATE); POLYLACTIC ACID; POLYMER; POLYSTYRENE DIVINYLBENZENE; PROGESTERONE; QUANTISON; RECOMBINANT HUMAN SERUM ALBUMIN; SORBITAN TRIOLEATE; STEROID; TRAMEINOLONE DIACETATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGENICITY; ARTIFICIAL EMBOLISM; CHEMICAL MODIFICATION; COLON; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; DENSITY; DIAGNOSTIC IMAGING; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOXICITY; DRUG TRANSPORT; FREEZE DRYING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPERTHERMIC THERAPY; INFLAMMATION; LIVER TUMOR; LUNG; MOLECULAR INTERACTION; MOLECULAR SIZE; MOLECULAR STABILITY; MOLECULAR WEIGHT; NONHUMAN; OSMOTIC PRESSURE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA HALF LIFE; REVIEW; SUSPENSION; SUSTAINED RELEASE PREPARATION; TECHNIQUE; TEMPERATURE SENSITIVITY; THERMOSTABILITY; TISSUE SPECIFICITY; ULTRASOUND; ZETA POTENTIAL;

EID: 0038555755     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10157     Document Type: Review

References (218)

1. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis SS. 1977. Effect of covalent attachment of polyethylene glycol on immuno-genicity and circulating life of bovine liver catalase. J Biol Chem 252:3582-3586.
2. Allan L, Cummings J, Willmott N, Whateley TL, Smyth JF. 1993. Incorporation and release of chemically intact micromycin C from albumin microspheres: high performance liquid chromatography evaluation. J Drug Target 1:317-324.
3. Alving CR, Verma JN, Bao M, Kryzych U, Amselem S, Green SJ, Wassef NM. 1992. Review: liposomes containing lipid A as a potent non-toxic adjuvant. Res Immunol 143:197-198.
4. Arshady R. 1988. Review: preparation of nano- and microspheres by vinyl polymerization condensation techniques. J Microcaps 5:101-114.
5. Arshady R. 1989a. Preparation of polymer nano- and microspheres by polymerization techniques. J Microcaps 6:1-12.
6. Arshady R. 1989b. Preparation of microspheres and microcapsules by interfacial polycondensation techniques. J Microcaps 6:13-28.
7. Arshady R. 1990. Albumin microspheres and microcapsules: Methodology of manufacture techniques. J Control Rel 14:111-113.
8. Arshady B, Ledwith A. 1983. Suspension polymerization and its application to the preparation of polymer supports. Reactive Poly 1:159-174.
9. Bach DS. 1999. Adherence of albunex to an apical left ventricular thrombus. J Am Soc Echocardiogr 2:761-762.
10. Baker RW, Lonsdale HK. 1974. Controlled release: mechanisms and rates. In: Tanquary AC, Lacey RE, editors. Controlled release of biologically active agents. New York: Plenum Press. p 15-22.
11. Bechtel W, Wright C, Wallace S, Mosier B, Mosier D, Mir S, Kudo S. 1986. An experimental evaluation of microcapsules for arterial chemoembolization. Radiology 161:601-604.
12. Beljaars L, Melgert BN, Meijer DKF, Molema G, Poelstra K. 2001. Neoglyco- and neopeptide albumins for cell-specific delivery of drugs to chronically diseased livers. In: Schreirer H, editor. Drug targeting technology physical, chemical, biological methods. Drugs and the pharmaceutical sciences, vol. 115. New York: Marcel Dekker. p 189-240.
13. Bevan DR, Shock RJG, Ellis BW. 1995. In: Paterson-Brown S, editor. Hamlinton Bailey's emergency surgery, 12th ed, Oxford: Butterworth-Heinemann. p 26-35.
14. Birnbaum B, Luo H, Nagai T, Fishbein MC, Peterson TM, Li S, Kricsfeld D, Porter TR, Siegel RJ. 1998. Noninvasive in vivo clot dissolution without a thrombolytic drug: recanalization of thrombosed iliofemoral arteries by transcutaneous ultrasound combined with intravenous infusion of microbubbles. Circulation 97:130-134.
15. Blau S, Levin N, Schwartz B, Rubinstein A. 2001. Adsorption of cationized bovine serum albumin onto epithelial crypt fractions of the rat colon. J Pharm Sci 90:1516-1522.
16. British Pharmacopoeia. 2001. Vol. II. Parenteral preparation: definition. London: Department of Health.
17. Brown JR, 1977. In: Albumin: Structure, Function and Uses. Rosener VM, Oratz M, Rothschild MA, editors. Oxford: Pergamon Press 27-52.
18. Burdine J, Ryder L, Sonnermaker R, DePuey G, Calderon. 1971. 99mTc-human albumin microspheres for lung imaging. M J Nucl Med 12:127-130.
19. Burgalassi S, Chetoni P, Saettone MT. 1996. Hydrogels for ocular delivery of pilocarine: preliminary evaluation in rabbits of the influence of viscosity and of drug solubility. Eur J Pharm Biopharm 42:385-392.
20. Burger JJ, Tomlinson E, McVie JG. 1985a. Microparticles intended for microvasculature blockage: drug incorporation and release. In: Buri P, Gumma A, editors. Drug targeting. Amsterdam: Elsevier. p 81-94.
21. Burger JJ, Tomlinson E, Mulder EMA, McVie JG. 1985b. Albumin microspheres for inter-arterial tumour targetting. I. Pharmaceutical aspects. Int J Pharm 23:333-344.
22. Burgess DJ, Hickey AJ. 1994. Microsphere technology and applications. In: Swarbrick J, Boylan JC. editors. Encyclopedia of pharmaceutical technology, vol. 10. New York: Marcel Dekker. p 1-30.
23. Burgess DJ, Davis SS, Tomlinson E. 1988. Potential use of albumin microspheres as a drug delivery system. I. Preparation and in vitro release of steroids. Int J Pharm 46:69-76.
24. Cao X, Stoichet MS. 1999. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 20:329-339.
25. Carter D, Ho J. 1994. Structure of serum albumin. Adv Protein Chem 45:153-203.
26. Chen Y, Willmott N, Anderxon J, Florence AT. 1988. Haemoglobin, transferin and albumin/polyaspartic acid microspheres as carriers for the cytotoxic drug adriyamycin. I. Ultrastructural appearance and drug content. J Control Rel 8:93-101.
27. Chien YW. 1992. Novel drug delivery system, 2nd ed. Revised and expanded, drugs and pharmaceutical sciences, vol. 50. New York: Marcel Dekker. p 269-300.
28. Church CC, Levene HB, Keene JM. 1993. Recent theoretical and experimental results with Albunex®, a contrast agent for diagnostic ultrasonography. ASA 125th Meeting, Ottawa 3aPA8.
29. Clarke RC, Courts A, 1977. The chemical reactivity of gelatin. In: The science and technology of gelatin. London: Academic Press 209-247.
30. Cleland JL, Powell MF, Shire SJ. 1993. Review: the development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Sys 10:307-377.
31. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. 1991. Controlled delivery system for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 8:713-720.
32. Costantino RH, Langer R, Klibanov AM, 1994. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sci 83:662-1669.
33. Cremers HF, Feijen J, Kwon G, Bae YH, McVie JG. 1990. Albuminheparin microspheres as carriers for cytostatic agents. J Control Rel 11:167-179.
34. Crommelin DJA, Hennink WE, Storm G. 2001. Drug targeting systems: fundamentals and applications to parenteral drug delivery. In: Hillery AM, Lloyd AW, Swarbrick J, editors. Drug delivery and targeting for pharmacists and pharmaceutical scientists. London: Taylor & Francis, pp 138-145.
35. Cummings J, Willmott N. 1985. Adriamycin-loaded albumin microspheres: quantitative assessment of drug incorporation and in vitro release by high performance liquid chromatography and high-speed multi-diode array spectrophotometric detection. J Chromatogr 343:208-212.
36. Dash AK, Khin-Khin A, Suryanarayan R. 2002. X-ray powder diffractometric method for quantitation of crystalline drug in microparticulate systems. I. Microspheres. J Pharm Sci 91:983-990.
37. Davis SS, Illum L. 1986. Colloidal delivery systems: Opportunities and Challenges. In: Tomlinson E, Davis SS, editors. Site-specific delivery, London: John Wiley & Sons, p 93-110.
38. Davis SS, Mills SN, Tomlinson E. 1987. Chemically cross-linked albumin microspheres for the controlled release of incorporated Rose Bengal after intramuscular injection into rabbits. J Control Rel 4:293-302.
39. Deasy PB. 1984. Microencapsulation and related drug process. Drugs and the pharmaceutical series, vol 20. Basel: Marcel Dekker. p 219-240.
40. Desir RM, Cheirif J, Bolli R, Zoghbi WA, Hoyt BD, Quinones MA. 1994. Assessment of regional myocardial perfusion with myocardial contrast echocardiography in a canine model of varying degrees of coronary stenosis. Am Heart J 127:56-63.
41. Dilova V, Shishkova V. 1993, Albumin microspheres as a drug delivery system for dexamethasone: pharmaceutical and pharmacokinetic aspects. J Pharm Pharmacol 45:987-989.
42. Due-Mauger A, Benoit JP, Puisieux F. 1986. Preparation and characterization of crosslinked human serum albumin microspheres containing 5-fluorouracil. Pharm Acta Helv 61:119-124.
43. El-Samaligny M, Rohdewald P. 1982. Tramcinolone diacetate nanoparticles, as sustained release drug delivery system suitable for parenteral administration. Pharm Acta Helv 57:201-204.
44. Etani H, Kimura K, Yoneda S, Tsuca Y, Isaka Y. 1982. Cerebral perfusion imaging with albumin microspheres tagged with Tc 99m and 1n 111 in cases with internal carotid occlusion. J Nucl Med 23:823-829.
45. Evans RL. 1972 US. Patent 3,663,687, assigned to Minnesota Mining and Manufacturing Co.
46. Fornusek L, Vetvicka V. 1986. Polymeric microspheres as diagnostic tools for cell surface marker tracing. CRC Crit Rev Ther Drug Carrier Syst 2:137-174.
47. Forsberg F, Golderg BB, Liu JB, Metron DA, Rawool NM. 1996. On the feasibility of real-time, in vivo harmonic imaging with proteineous microspheres. J Ultrasound Med 15:853-860.
48. Forsberg F, Goldberg BB, Liu JB, Merton DA, Rawool NM, Shi WT. 1999. Tissue-specific US contrast agent for evaluation of hepatic and splenic parenchyma. Radiology 210:125-132.
49. Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Okui K, Sugibayashi K, Morimoto Y. 1985a. Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. Cancer 56:2404-2410.
50. Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Okui K, Sugibayashi K, Morimoto Y. 1985b. Mitomycin C carrying microspheres as a novel method of drug delivery. Cancer Drug Del 2:173-281.
51. Galanti G, Jayaweera AR, Villanueva FS, Glasheen WP, Ismail S. 1993. Transpulmonary transit of microbubbles during contrast echocardiography implications for estimating cardiac output and pulmonary blood volume. J Am Soc Echocardiog 6:272-278.
52. Gallo JM, Hung CT, Perrier DG. 1984. Analysis of albumin microsphere preparation. Int J Pharm 22:63-74.
53. Giunchedi P, Chetoni P, Conte U, Saettone MF. 2000. Albumin microspheres for ocular delivery of piroxicam. J Pharm Sci Commun 6:149-153.
54. Goosen MFA, Leung LYF, Chou S, Sun AM. 1982. Insulin-albumin microbeads: an implantable, biodegradable system. Biomat Med Dev Art Org 10:205-218.
55. Gregoriadis G. 1977. Targeting of drugs. Nature 265:407-411.
56. Gregoriadis G, Neerunjun ED. 1975. Homing of liposomes to target cells. Biochem Biophys Bes Commn 65:537-544.
57. Grinstaff MW, Suslick KS. 1991. Air-filled proteinaceous microbubbles: Synthesis of an echo-contrast agent. Proc Natl Acad Sci USA 88:7708-7710.
58. Grooves MJ. 1999. Prenteral drug delivery systems. In: Mathiowitz E, Kreitz MR, Peppas LB, editors. Encyclopedia of controlled drug delivery, vol. 2. New York: John Wiley & Sons. p 743-777.
59. Gupta PK, Hung CT. 1989a. Review. albumin microspheres. I. Physico-chemical characteristics. J Microencap 6:427-462.
60. Gupta PK, Hung CT. 1989b. Albumin microspheres. II. Applications in drug delivery. J Microencap 6:463-472.
61. Gupta PK, Hung CT 1990. Albumin microspheres. V. Evaluation of parameters controlling the efficacy of magnetic microspheres in the targeted delivery of adriamycin in rats. Int J Pharm 59:57-67.
62. Gupta PK, Hung CT, Perrier DG. 1986a. Albumin microspheres. I. Release characteristics of adriamycin. Int J Pharm 33:137-146.
63. Gupta PK, Hung CT, Perrier DG. 1986b. Albumin microspheres. II. Effect if stabilization temperature on the release of adriyamycin. Int J Pharm 33:147-153.
64. Gupta PK, Gallo JM, Hung CT, Perrier DG. 1987. Influence of stabilization temperature on the entrapment of adriamycin in albumin microspheres. Drug Dev Ind Pharm 13:1471-1482.
65. Gupta PK, Hung CT, Lam FC. 1989. Factorial design based optimization of the formulation of albumin microspheres containing adriamycin. J Microencap 6:147-160.
66. Guzman-Navarro M, Abeger-Monteguds A, Sellles-Flores E. 1987. Drug transport systems: liposomes. Farm Clin Spain 4:111-128.
67. Halls NA. 1994. Achieving sterility in medical and pharmaceutical products. Drugs and pharmaceutical sciences, vol. 64. New York: Marcel Dekker. p 1-15.
68. Halpern EJ, Verkh L, Forsberg F, Gomella LG, Mattrey RF, Goldberg BB. 2000. Initial experience with contrast-enhanced sonography of the prostate. AJR Am J Roentgenol 174:1575-1580.
69. Heller J, Baker RW. 1980. Theory and practice of controlled release of bioactive materials. In: Baker RW, editor. Controlled release of bioactive materials. New York: Academic Press. p 1-17.
70. Horrobin DF. 1968. In: Medical physiology and biochemistry. London: Edward Arnold. p 47-56.
71. Hung CT, McLeod AD, Gupta PK. 1990. Formulation and characterization of magnetic polyglutaraldehyde nanoparticles as carriers for poly-1-lysine-methotrexate. Drug Dev Ind Pharm 16:509-521.
72. Illum L, Davis SS. 1983. Effect of non-ionic surfactant poloxamer 338 on the fate and dispersion of polystyrene microspheres following intravenous administration. J Pharm Sci 72:1086-1089.
73. Illum L, Davis SS, Wilson CG, Thomas NW, Frier M, Hardy JG. 1982. Blood clearance and organ deposition of intravenously admnistered colloidal particles. Effect of particle size, nature and shape. Int J Pharm 12:135-146.
74. Ishizaka T, Koishi M. 1983. In vitro drug release from egg albumin microcapsules. J Pharm Sci 72:1057-1061.
75. Ishizaka T, Endo K, Koishi M. 1981. Preparation of egg albumin microcapsules and microspheres. J Pharm Sci 70:583-363.
76. Ishizaka T, Motojima M, Kounosu S, Koishi M. 1986. In vitro release of poly (ethylene oxides) form serum albumin microspheres. Chem Pharm Bull 34:3341-3347.
77. Jalsenjak I. 1992. In: Donbrow M, editor. Microcapsules and nanoparticles in pharmacy and medicine. Boca Raton, FL: CRC Press; p 193-218.
78. Jantzen GM, Robinson JR. 1996, Sustained- and controlled-release drug delivery systems. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics, 3rd ed. Revised and expanded. Drugs and the pharmaceutical sciences, vol. 72. New York: Marcel Dekker. p 575-609
79. Johnson OL, Tracy MA. 1999. Peptide and protein drug delivery. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery, vol. 2. New York: John Wiley & Sons. p 816-833.
80. Jones C, Burton MA, Gray BN. 1989. Albumin microspheres as vehicles for the sustained and controlled release of doxorubicin. J Pharm Pharmacol 1989 41:813-816.
81. 141CE-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. J Pharm Sci 69:755-762.
82. Kanke M, Morlier E, Geissler R, Powell D, Kaplan A, DeLuca PP. 1986. Interaction of microspheres with blood constituents. II. Uptake of biodegradable particles of microphages. J Parent Sci Technol 40:114-118.
83. Kasprzak JD, Ten Cate FJ. 1998. New ultrasound contrast agents for left ventricular and myocardial opacification. Herz 23:474-482.
84. Kato T, Nemoto R, Mori H, Kunagi I. 1980. Sustained-release properties of microencapsnlated mitomycin C with ethylcellulose infused into the renal artery of the dog. Cancer 46:14-21.
85. Kato T, Nemoto R, Mori H, Takahashi M, Harada M. 1981. Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver, bone and intrapelvic organs. Cancer 1981;48:674-680.
86. Katti D, Krishnamurthi N. 1999. Preparation of albumin microspheres by improved process. J Microencap 16:231-242.
87. Kedar RP, Cosgrove D, McCready VR, Bamber JC, Carter ER. 1996. Microbubble contrast agent for color Doppler US: effect on breast masses. Radiology 198:679-686.
88. Keller MV, Feinstein SB, Briller RA. 1986. Automated production and analysis of ecocontrast agents. J Ultrasound Med 5:493-498.
89. Keller MW, Feinstein SB, Watson DD. 1987. Successful left ventricular opacification following peripheral venous injection of sonicated contrast agents and experimental evaluation. Am Heart J 114:570-575.
90. Kim CK, Lee JK, Lah WL. 1986. Development of specific organ targeting drug delivery systems. II. Physico-chemical study on the cross-linked albumin microspheres containing cytarabine. Arch Pharm Res 90:39-43.
91. Kim CK, Lee MK, Han JH, Lee BJ. 1994. Pharmacokinetics and tissue distribution of methotrexate after intravenous injection of differently charged liposome-entrapped methotrexate to rats. Int J Pharm 108:21-29.
92. Kosar J, Atkins GM Jr. 1968. US Patent 3,406,119, assigned to Keuffel & Esser Co.
93. Kramer PA. 1974. Albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 63:1646-1647.
94. Kramer PA, Burnstein T. 1976. Phagocytosis of microspheres containing an anticancer agent by tumor cells in vitro. Life Sci 19:515-520.
95. Kratz F, Fichtner I, Schumarcher P, Roth T, Feibig HH, Unger C. 1997. Antitumor activity of acid labile transferrin and albumin doxorubicin conjugates in vitro and in vivo human tumor xerograft models. Eur J Cancer 33:S175.
96. Kreuter J. 1994. Nanocapsules. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology, vol. 10. New York: Marcel Dekker. p 165-190.
97. Kumagai AK, Eisenberg JB, Pardridge WM. 1987. Absorptivemediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain carrier transport. J Biol Chem 262:15214-15219.
98. Kumar V. Banker GS. 1996. Target oriented drug delivery, systems. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics, 3rd ed, Revised and expanded. Drugs and the pharmaceutical sciences, vol. 72. New York: Marcel Dekker. p 611-680.
99. Kumar MV, Jayawi SB, Gupta VK. 1994, Preparation and in vitro evaluation of streptomycin sulfate loaded albumin microspheres for lung targeting. Pharmazie 49:691-692.
100. Kurtzhals P, Havelund S, Jonassen Y, Kiehr B, Ribel U, Markussen J, 1996. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 85:304-308.
101. Kwon GS, Bae YH, Cremers H, Feijen J, Kim SW. 1992. Release of macromolecules from albumin-heparin microspheres. Int J Pharm 79:191-198.
102. Labhasetwar VD, Dorle AK. 1990. Nanoparticles controlled drug delivery, system for primaquine and metronidazole. J Control Rel 12:113-119.
103. Lalla JK, Ahuja PL. 1991. Drug targeting using non-magnetic and magnetic albumin-globulin mix microspheres of mefenamic acid. J Microencap 8:37-52.
104. Lanza GM, Wallace KD, Fischer SE, Christy DH, Scott MJ, Trousil RL, Cacheris WP, Miller JG, Gaffney PJ, Wickline SA. 1997. High-frequency ultrasonic detection of thrombi with a targeted contrast system. Ultrasound Med Biol 23:863-870.
105. Leach KJ. 1999. Cancer, drug delivery to treat - local & systemic. In: Mathiowitz E, Kreitz MR, Peppas LB, editors. Encyclopedia of controlled drug delivery, vol. I. New York: John Wiley & Sons. p 119-143.
106. Lee VHL, Robinson JR. 1979. Mechanistic and quantitative evaluation of precorneal pilocarpne disposition in albino rabbits. J Pharm Sci 68:673-684.
107. Lee TK, Sokolski TD, Royer GP. 1981. Serum albumin beads: an injectable, biodegradable system for the sustained release of drugs. Science 213:223-235.
108. Leucuta SE, Risca R, Daicoviciu D, Portutiu D. 1988, Albumin microspheres as a drug delivery system for epirubicin: pharmaceutical, pharmacokinetic and biological aspects. Int J Pharm 41:213-217.
109. Levy MY, Benita S. 1989. Design and characterization of a submicronized O/W emulsion of diazepam for parenteral use. Int J Pharm 54:103-112.
110. Liu JB, Merton DA, Goldberg BB, Rawool NM, Shi WT, Forsberg FJ. 2002. Contrast-enhanced two- and three-dimensional sonography for evaluation of intra-abdominal hemorrhage. Ultrasound Med 21:161-169.
111. Longo WE, Iwata H, Chindheimer TA, Goldberg EP. 1982. Preparation of hydrophilic albumin microspheres using polymeric dispersing agents. Pharm Sci 71:1323-1328.
112. Longo WE, Iwata H, Lindheimer T, Goldberg EP. 1983, Preparation and drug release properties of albumin-polyglutamic acidadriamycin microspheres. Polym Prepr 24:56-57.
113. Makoid MC, Robinson JR. 1978. Pharmacokineties of topically applied pilocarpine in the albino rabbit eye. J Pharm Sci 68:435-443.
114. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein in pharmaceuticals. Pharm Res 6:903-915.
115. Marcus R, Coulston AM. 1990. Fat-soluble vitamins A, K and E. In: Gilman GA, Rail TW, Nies AS, Taylor P, editors, The pharamcological basis of therapeutics, New York: Pergamon Press. p 1553-1571.
116. McDiken WN, Hoskins PR. 2000. Physics: principles, practice and artifacts. In: Allan PL, Dubbins PA, Pozniak MA, McDicken WN, editors. Clinical doppler ultrasound. Toronto: Churchill Livingstone, p 1-25.
117. Mean GE, Feeney RE. 1995. Reductive alkylation of proteins, Anal Biochem 224:1-16.
118. Mills SN, Davis SS. 1987. Controlled drug delivery In: Illum L, Davis SS. editors. Polymers in controlled drug delivery. UK: Write Bristol. p 1-15.
119. Miyazaki S, Hashiguchi N, Sugiyama M, Takada M, Morimto Y. 1986, Fibrinogen microspheres as novel drug delivery systems for anticancer drugs. Chem Pharm Bull (Tokyo) 34:1370-1375.
120. Mohankrishnan R, Chignell CF, Cox RH. 1985. Chloride ion nuclear magnetic resonance spectroscopy probe studies of copper and nickel binding to serum albumins. J Pharm Sci 74:61-63.
121. Mora M, Pato J. 1993. Preparation of egg albumin microparticles for oral application, J Control Rel 25:107-113.
122. Morimoto Y, Fujimoto S. 1985. Albumin microspheres as drug carriers. CRC Crit Rev Ther Drug Carrier Syst 2:19-63.
123. Morimoto Y, Aldmoto M, Sugibayahsi K, Nadai T, Kato Y. 1980. Drug-carrier property of albumin microspheres in chemotherapy. Antitumor effect of single-shot or multiple shot ad-ministration of microsphere-entrapped 5-fluorouracil on Ehrlich ascites or solid tumor in mice. Chem Pharm Bull 28:3087-3092.
124. Morimoto Y, Sugibayashi K, Kato Y. 1981. Drug carrier properties of albumin microspheres in chemotherapy. 5. Antitumor effect of microsphere entrapped adriamycin on liver metastasis of AH 7974 cells in rats. Chem Pharm Bull 29:1433-1438.
125. Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, Monaghan M, Porter TR, Shaw LJ, Villanueva FS. 2000. Contrast echocardiography: current and future applications. J Am Soc Echocardiogr 13:331-342.
126. Narazaki R, Hamada M, Otagari M. 1966. Covalent binding between bucillamine derivatives and human serum albumin. Pharm Res 13:1317-1321.
127. Oliva A, Santovefia A, Llabres M, Farifia JB. 1999. Stability study of human serum albumin pharmaceutical preparations. J Pharm Pharmacol 51:385-392.
128. Öner L, Groves MJ. 1993. Properties of human albumin microparticles prepared by chilled cross-linked technique. J Pharm Pharmacol 45:866-870
129. Onyuksel HA, Demos SM, Lanza GM, Vonesh MJ, Klegerman ME, Kane BJ, Kuszak J, Mcpherson DD. 1996. Development of inherently echogenic liposomes as an ultrasound contrast agent. J Pharm Sci 85:486-490.
130. Ophir J, Parker KJ. 1989. Contrast agents in diagnostic ultrasound. Ultrasound Med Biol 15:319-333.
131. Oppenheim RC. 1981. Solid colloidal drug delivery systems: nanoparticles. Int J Pharm 8:271-934.
132. Pal PR, Pal TK. 1987. Studies on sulphamethazole microcapsules in reference to the effect of micrometric properties on release characteristics. Indian Drugs 24:430-437.
133. Park K, Shalaby WSW, Park H. 1993, Biodegradable hydrogels for drug delivery. Switzerland: Technomic. p 67-98.
134. Peppas LB. 1995. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm 116:1-9.
135. Porter TR, LeVeen BF, Fox R, Kricsfeld A, Xie F. 1996, Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin microbubbles, Am Heart J 132:964-968.
136. Przybrowski M, Lachnik E, Wiza J, Licinska I. 1982. Preparation of HSA microspheres in a one step thermal denaturation process aerosol carried in a gas medium. Eur J Nucl Med 7:71-72.
137. Przybrowski M, Lachnik E, Wiza J, Licinska I. 1983, HSA microspheres. Claude R, editor. Nucl Med Biol Adv Proc World Congrs 3rd vol. I, Oxford: Pergamon. p 249-251.
138. Rand ML, Murray RK. 2000. Plasma proteins, immunoglobulins, and blood coagulation. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, editors. Harper's biochemistry, 25th international ed, Stanford, CT: Appleton 762.
139. Ratcliffe JH, Hunneyball IM, Smith A, Wilson CG, Davis SS. 1984. Preparations and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J Pharm Pharmcol 36:431-436.
140. Reddy DN, Udupa N. 1993. Formulation and evaluation of oral and transdermal preparation of flurviprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm 19:843-852.
141. Reddy PB, Dorle AK, Krishna DR. 1990, Albumin microspheres: effect of process variables on size distribution and in vitro release. Drug Dev Ind Pharm 16:1792-1803.
142. Reisner SA, Ong LS, Lichtenberg GS, Amico AF, Shapiro JR, Allen MN, Meltzer RS. 1989. Myocardial perfusion imaging by contrast echocardiography with use of intracoronary sonicated albumin in humans. J Am Coll Cardiol 14:660-665.
143. Rhodes BA, Zolle I, Buchanan JW, Wagner HW Jr. 1969. Radioactive albumin microspheres for studies of the pulmonary circulation. Radiology 92:1453-1460.
144. Rhodes BA, Stern H, Buchanan J, Zolle I, Wagner H. 1971. Lung scanning with 99m Tc microspheres. Radiology 99:613-621.
145. Rolland A, Begue JM, Le-Verge R, Guillouza A. 1989. Increase of doxorubicin penetration in cultured rats hepatocytes by its polymethacrylic nanoparticles. Int J Pharm 53:67-73.
146. Roller E, Buzzigoli G, Plassi G. 1972. Serum triiodothyronine uptake using albumin microspheres in assessment of thyroid function. J Nucl Med 13:893-898.
147. Royer GP. 1982. US Patent 4,349,530, assigned to The Ohio State University, Columbos, OH.
148. Royer GP, Lee TK, Sokoloski TD. 1983, Entrapment of bioactive compounds within albumin beads. J Parenter Sci Tech 37:34-37.
149. Rubino OP, Kowalsky R, Swarbrick J. 1993. Albumin micro-spheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking, and drug release. Pharm Res 10:1059-1065.
150. Rubinstein A, Tirosh B. 1994. Mucus gel thickness and turnover in the gastrointestinal tract of the rat, responses to chloinergic stimulus and implication for mucoadhesion. Pharm Res 11:794-799.
151. Saettone MF, Sallminen L. 1999. Ocular inserts for topical delivery. Adv Drug Del Rev 16:95-106.
152. Saettone MF, Chetoni P, Torracca MT, Burgalassi S, Giannaccini B. 1989. Evaluation of mucoadhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharm 51:203-212.
153. Sawaya A, Benoit JP, Benita S. 1987. Binding mechanism of doxorubicin in ion-exchange albumin microcapsules. J Pharm Sci 76:475-480.
154. Scheffel U, Rhodes BA, Natarajan TK, Wagner HNJr. 1972. Albumin microspheres for studies of reticuloendothelial system. J Nucl Med 13:498-503.
155. Schoen FJ, Kintanar EB, Osol RG, Lee E. 1986. Pulmonary reaction to intravenously injected polymer beads. J Biomed Mater Res 20:709-721.
156. Senyei AE, Reich SD, Gonczy C, Widder KJ. 1981. In vivo kinetics of magnetically targeted low-dose doxorubicin. J Pharm Sci 70:389-391.
157. Shah MV, De Gennaro MD, Suryakusuma H. 1987. An evaluation of albumin microcapsu]es prepared using a multiple emulsion technique. J Microencaps 4:223-238.
158. Sheu MT, Sokolosld TD. 1986. Entrapment of bioactive compounds within native albumin beads. III. Evaluation of parameter affecting drug release. J Parenter Sci Technol 40:259-265.
159. Sheu MT, Moustafa MA, Sokolowski TD. 1986. Entrapment of bioactive compounds within native albumin beads. II. Effects of heat and extent of cross-linking on microbead properties. J Parenter Sci Technol 40:253-258.
160. Sherwin JE. 1989. Liver Function. In: Kaplan LA and Pesce AJ, editors. In: Clinical Chemistry: Theory, Analysis and Correlation, 2nd ed. St. Louis USA: The CV Mosby Company 359-372.
161. Shorr RGL. 1999. Cancer, drug delivery, to treat - prodrugs. In: Mathiowitz E, Kreitz MR, Peppas LB, editors. Encyclopedia of controlled drug delivery, vol. I. New York: John Wiley & Sons. p 143-161.
162. Simon SI, Schmid-Schonbein GW. 1988. Biophysical aspects of Micro-sphere engulfment by human neutrophils. Biophys J 3:163-173.
163. Si-Nang L, Carlier PF, Delort P, Gazzola J, Lafont D. 1973. Determination of coating thickness of microcapsules and influence upon diffusion. J Pharm Sci 62:452-455.
164. Singh ON, Burgess DJ, 1989. Characterization of albumin-alginic acid complex coacervation. J Pharm Pharmacol 41:670-673.
165. Stahl PD, Diment S. 1988. Macrophage endosome protease, which degrade endocytosed protein ligands. J Biol Chem 263:6093-6100.
166. Stedman's Medical Dictionary. 2000. 27th ed. Philadelphia: Lippincott Williams & Wilkins.
167. Sugibayashi K, Akimoto M, Morimoto Y, Nadai T, Kato Y. 1979a, Drug-carrier property of albumin microspheres in chemo-therapy. III. Effket of microsphere-entrapped 5-fluorouracil on Ehrlich ascites carcinoma in mice. J Pharm Dyn 2:350-355.
168. Sugibayashi K, Morimoto Y, Nadai T, Kato Y, Hasegawa A, Arita T. 1979b. Drug-carrier property of albumin microspheres in chemo-therapy. II. Preparation and tissue distribution in mice of micro-sphere-entrapped 5-fluorouracil. Chem Pharm Bull 27:204-209.
169. Tae-Kyoung K, Burgess DJ. 2001. Formulation and release characteristics of poly(lactic co-glycolic acid) microspheres containing chemically modified protein. J Pharm Pharmacol 53:23-31.
170. Tall AR, Hogan V, Ankinazi L, Small DM. 1978. Interaction of plasma high density lipoproteins with dimyristyllecithinmultilamellar liposomes. Biochemistry 17:322-326.
171. Tetalman MR, Hoffer PB, Heck LL, Kunzmann A, Gottschalk A. 1973. Perfusion lung scan in normal volunteers. Radiology 106:593-594.
172. Toguchi H. 1999. Sterility assurance of microspheres. J Control Rel 62:51-55.
173. Tomiya N, Watanabe K, Awaya J, Kurono M, Fujii S. 1985. Modification of acyl-plasmin-streptokinase complex with polyethylene glycol reduction of sensitivity to neutralizing antibody. FEBS Lett 193:44-48.
174. Tomlinson E. 1983. Microspheres delivery systems for drug targeting and controlled release. Int J Pharm Technol Prod Manuf 4:49-57.
175. Tomlinson E, Burger JJ. 1985. Incorporation of water-soluble drugs in albumin microspheres. Methods Enzymol 112:27-43.
176. Tomlinson E, Burger JJ. 1987. Monolithic albumin particles as drug carriers. In: Illum L, Davis SS, editors. Polymers in controlled drug deliver. UK: Write Bristol. p 25-48.
177. Tomlinson E, Burger JJ, Schoonderwoerd EMA, McVie JG. 1984. Human Serum albumin microspheres for intraarterial drug targeting of cytostatic compounds. Pharmaceutical aspects and release characteristics. In: Davis SS, Illum L, McVie JG, Tomlinson E, editors. Microspheres and drug therapy. Pharmaceutical, immunological and medical aspects. Amsterdam: Elsevier. p 75-89.
178. Torrado JJ, Cadorniga R. 1989a. Albumin microcapsules, microspheres and nanoparticles as new systems of medication administration. Farmacia Clinica 6:724-733.
179. Torrado JJ, Illum L, Davis SS. 1989b. Particle size and size distribution of albumin microspheres produced by heat and chemical stabilization. Int J Pharm 51:85-93.
180. Torrado S, Torrado JJ, Cadorniga R. 1992. Topical application of albumin microspheres containing vitamin A: drug release and availability. Int J Pharm 86:147-152.
181. Tsai D, Howard SA, Hogen TF, Malanga CJ, Kandazari SJ Ma JKH. 1986. Preparation and in vitro evaluation of polylactic acid - mitomycin C microcapsules. J Microencap 3:181-185.
182. Unger EC. 1992. US Patent 5,149,319 assigned to Camino La Cebadilla, Tucson, AZ.
183. Unger EC, Matsunagao TO, MeCreery T, Schumann P, Sweitzer R, Quigley R. 2002. Therapeutic applications of microbubbles. Eur J Radiol 42:160-168.
184. United States Pharmacopoeia. The National Formulary. 2000. 24th ed. Albumin human. Rockville, MD: United States Pharmacopoeial Convention.
185. Visseher GE, Robinson RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. 1986. Biodegradation of and tissue reaction to poly DL-lactide microcapsules. J Biomed Mater Res 20:667-676.
186. Vocci MJ, Robin AL, Wahl JC, Mayer P, Graves A, York B, Enger C, Sutton J. 1992. Preformulation and drop size of aproclonidine hydrochloride. Am J Ophthalmol 113:154-160.
187. Vyas SP, Bhatnagar S, Gogoi PJ, Jain NK. 1991. Preparation and characterization of HSA-propanolol microspheres for nasal administration. Int j Pharm 69:5-12.
188. Wadhwani KC, Shimon-Hophy M, Rapoport SI. 1992. Enhanced permeabilities of cationized-bovine serum albumins at the bloodnerve and blood-brain barriers in awake rats. J Neurosci Res 32:404-414.
189. Wagner HN Jr, Rhodes BA, Saski Y, Ryan JP. 1969. Studies of the circulation with radio active microspheres. Invest Radiol 4:374-386.
190. Wallace S, Chuang V, Carrasco C, Charansagaverj C, Bechtel W, Wright KC, Gianturco C. 1988. Physioanatomic concepts and radiologic techniques for
191. Weissmann G. 1976. Experimental enzymes replacement in genetic and other disorders. Hosp Pract 11:49-58.
192. West JB, 1990. Blood and the plasma proteins: functions and composition of blood. In: West JB, editor. Best & Taylor's Physiological Basis of Medical Practice, International Edition, 12th ed. MD 21202, USA: Williams and Wilkins 332-338.
193. Wetzel R, Becker M, Behlke J, Billwitz H, Bohm S, Ebert B, Hamann H, Krumbiegel J, Lassmann G. 1980, Temperature behavior of human serum albumin. Eur J Biochem 104:469-478.
194. Wheatley MA, Narayana P 1999. Diagnostic use of microspheres. In: Mathiowitz E, Kreitz MR, Peppas LB, editors. Vol. I. New York: John Wiley 340.
195. Wible JH Jr, Adams MD, Sherwin PF, Wojdyla JK, Parsons AK, Atala A, Fowlkers JB, Needleman L. 1994. Narcardiac applications of albunes. Invest Radio 29:S145-S148.
196. Widder KJ, Senyei AE, Scarpelli DG. 1978. Magnetic microspheres: a model system specific drug delivery in vivo. Proc Soc Exp Biol Med 158:141-146.
197. Widder K, Flouret G, Senyei A. 1979. Magnetic microspheres: synthesis of a novel parenteral drug carrier. J Pharm Sci 68:79-81.
198. Widder KJ, Senyei AE, Sears B. 1982. Experimental methods in cancer therapeutics. J Pharm Sci 71:379-387.
199. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. 1983. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer 20:377-395.
200. Williams AR, Kubowicz G, Cramer E, Schlief R. 1991. The effects of the microbubble suspension SH U 454 (Echovist) on ultrasound-induced cell lysis in a rotating tube exposure system. Echocardiology 8:423-433.
201. Willmott N, Cummings J. 1987. Increased anti-tumor effect of adriamycin loaded albumin microspheres is associated with anaerobic bioreduction of the drug tumor. Biochem Pharmcol 36:521-526.
202. Willmott N, Harrison PJ. 1988. Characterization of freeze-dried albumin microspheres containing anti-cancer drug adriamycin. Int J Pharm 43:161-166.
203. Willmott N, Cummings J, Stuart JFB, Florence AT. 1985. Adriamycin loaded albumin microspheres: Preparation, in vivo distribution and release in rat. Biopharm Drug Dispos 6:91-104.
204. Willmott N, Chen Y, Florence AT. 1988. Haemoglobin, eransferrin and albumin/polyaspartic acid microspheres as carriers for the cytotoxic drug adriamycin. II. In vitro drug release rates. J Control Rel 8:103-109.
205. Wright K, Wallace S, Mosier B, Mosier D. 1988. Microcapsules for arterial chemoembolization: Appearance and in vitro drug release characteristics. J Microencap 5:13-20.
206. Yang DJ, Li Chun, Nikiforow S, Gretzer MB, Kuang Li-Ren, Lopez MS. 1994. Diagnostic and therapeutic potential of poly(benzyl Lglutamate). J Pharm Sci 83:328-331.
207. Yannas IV, Tobolsky AV. 1967. Cross-linking of gelatin by dehydration. Nature 215:508-510.
208. Yapel AF Jr. 1979. US Patent 4,147,767 assigned to Minnesota Mining and Manufacturing Co.
209. Yapel AF Jr. 1985. Albumin microspheres: heat and chemical stabilization. Methods Enzymol 112:3-18.
210. Yokel RA, Sabo JP, Simmons GH, DeLuca PP. 1981. Acute toxicity of latex microspheres. Toxicol Lett 9:165-170.
211. Yolles S, Eldrugde JE, Woodland JHR. 1979. Sustained delivery of drugs from polymer/drug mixtures. Polymer News 1-9.
212. Yong Y, Wu D, Fernandes V, Kopelen HA, Shimoni S, Nagueh SF, Callahan JD, Bruns DE, Shaw LJ, Quinones MA, Zoghbi WA. 2002. Diagnostic accuracy and cost-effectiveness of contrast echocardiography on evaluation of cardiac function in technically very difficult patients in the intensive care unit. Am J Cardiol 89:711-718.
213. Yoshioka T, Hashida M, Muranishi S, Sezald H. 1981. Specific delivery of mitomycin C to the liver, spleen and lung: nano- and microspherical carriers of gelatin. Int J Pharm 81:131-141.
214. Zeng XM, Martin GP, Marriott C. 1994. Albumin microspheres as a means of drug delivery to the lung: analysis of the effects of process variables on particle sizes using factorial design methodology. Int J Pharm 107:205-210.
215. Zeng SM, Martin GP, Marriott C. 1995. Preparation and in vitro evaluation of tetrandrine-entrapped albumin micro-spheres as an inhaled drug delivery system. Eur J Pharm Sci 3:87-93.
216. Zimmer A, Kreuter J. 1995. Microspheres and nanoparticles used in ocular delivery systems, Adv Drug Del Rev 16:61-73.
217. Zimmer AK, Chetoni P, Saettone MF, Zerbe H, Kreuters J. 1995. Evaluation of pilocarpine loaded albumin particles as controlled drug delivery, systems for the eye. 2. Co-administration with bioadhesive and viscous polymers. J Control Rel 33:31-46.
218. Zolle I, Rhodes BA, Wagner HN Jr. 1970. Preparation of metabolizible radioactive albumin microspheres for studies of the circulation. Int J Appl Radio Isotopes 21:155-167.